The immunogenicity and safety of the BBIBP-CorV (Sinopharm) inactivated SARS-COV-2 vaccine: A prospective observational study in Indonesia

被引:0
|
作者
At Thobari, Jarir [1 ]
Sattwika, Prenali Dwisthi [2 ]
机构
[1] Univ Gadjah Mada, Dept Pharmacol & Therapy, Fac Med Publ Hlth & Nursing, Yogyakarta, Indonesia
[2] Univ Gadjah Mada, Dept Internal Med, Fac Med Publ Hlth & Nursing, Yogyakarta, Indonesia
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
1264
引用
下载
收藏
页码:597 / 597
页数:1
相关论文
共 50 条
  • [22] Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
    Abdelhafiz, Ahmed Samir
    Ali, Asmaa
    Kamel, Mahmoud M.
    Ahmed, Eman Hasan
    Sayed, Douaa M.
    Bakry, Rania M.
    VACCINES, 2022, 10 (09)
  • [23] Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine
    Toback, Seth
    Marchese, Anthony M.
    Warren, Brandy
    Ayman, Sondos
    Zarkovic, Senka
    Eltantawy, Islam
    Mallory, Raburn M.
    Rousculp, Matthew
    Almarzooqi, Fahed
    Piechowski-Jozwiak, Bartlomiej
    Bonilla, Maria-Fernanda
    Bakkour, Agyad Ebrahim
    Hussein, Salah Eldin
    Al Kaabi, Nawal
    VACCINE, 2024, 42 (07) : 1777 - 1784
  • [25] Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study
    Puspitasari, Metalia
    Sattwika, Prenali D. D.
    Rahari, Dzerlina S. S.
    Wijaya, Wynne
    Hidayat, Auliana R. P.
    Kertia, Nyoman
    Purwanto, Bambang
    Thobari, Jarir At
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [26] Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study
    Metalia Puspitasari
    Prenali D. Sattwika
    Dzerlina S. Rahari
    Wynne Wijaya
    Auliana R. P. Hidayat
    Nyoman Kertia
    Bambang Purwanto
    Jarir At Thobari
    Scientific Reports, 13
  • [27] SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
    Etemadifar, Masoud
    Sedaghat, Nahad
    Nouri, Hosein
    Lotfi, Noushin
    Chitsaz, Ahmad
    Khorvash, Reza
    Zolfaghari, Hamed
    Movaghar, Alireza Ghasemi
    Pourabbas, Mohammad
    Salari, Mehri
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [28] Effectiveness and Safety of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) among Healthcare Workers: A Seven-Month Follow-Up Study at Fifteen Central Hospitals
    Ashmawy, Rasha
    Kamal, Ehab
    Amin, Wagdy
    Sharaf, Sandy
    Kabeel, Samar
    Albiheyri, Raed
    El-Maradny, Yousra A.
    Hassanin, Ebtisam
    Elsaka, Noura
    Fahmy, Ola
    Awd, Ahmed
    Aboeldahab, Heba
    Nayle, Mai
    Afifi, Magda
    Ibrahim, Marwa
    Rafaat, Raghda
    Aly, Shahinda
    Redwan, Elrashdy M.
    VACCINES, 2023, 11 (05)
  • [29] Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
    Sedaghat, Nahad
    Etemadifar, Masoud
    Lotfi, Noushin
    Sayahi, Farnaz
    Chitsaz, Ahmad
    Salari, Mehri
    Ghasemi Movaghar, Alireza
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
    Noel Badano, Maria
    Sabbione, Florencia
    Keitelman, Irene
    Pereson, Matias
    Aloisi, Natalia
    Colado, Ana
    Victoria Ramos, Maria
    Ortiz Wilczynski, Juan Manuel
    Gabriel Pozner, Roberto
    Castillo, Luis
    Wigdorovitz, Georgina
    de Bracco, Maria Marta E.
    Fink, Susana
    Chuit, Roberto
    Bare, Patricia
    MOLECULAR IMMUNOLOGY, 2022, 143 : 94 - 99